Nicholas Saraceno, Editor

A cohort study aims to connect the dots between incident AWVs among older adults with the first ADRD or MCI diagnosis who receive Medicare fee-for-service benefits.

With the implementation of unit-level traceability, the collaboration is expected to provide additional visibility not only within the aseptic manufacturing process, but the entire supply chain overall.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, describes the value of advocacy and other solutions in under-served areas.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, explains how pending legislation can improve patient access, and how these are helping with recognizing pharmacists as HCPs.

The hub is intended to assist customers with achieving better sustainability by providing the necessary tools to do so.

Getting a handle on level of compliance-readiness for the Drug Supply Chain Security Act deadline—now just weeks away.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, details why these pharmacy deserts have become so widespread.

The goal is to provide greater access to HIV prevention drugs in low-income countries.

The Healthcare Distribution Alliance's latest seminar was as timely as ever, with the end of the stabilization period for DSCSA implementation drawing closer.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, clarifies the meaning behind pharmacy deserts, along with reasons for their increase in prominence.

The company—whose foundation has committed $1.5 million for in donations for recovery—is currently working on a plan that will help limit supply disruption.

In the final part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, predicts how the future of data accessibility will unfold.

Are these statistical characteristics—along with social determinants of health—associated with denials of preventive care claims?

In the third part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, details the importance of E2E visibility.

Steve Silvestro explains the value of artificial intelligence in launch plans, benefits to integrating DTC and HCP marketing strategies, and more.

In the second part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, explains the sales and operations planning (SO&P) process that can help create logistical efficiencies.

The session details how these teachings span the entire pharma supply chain.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, discusses obstacles encountered by shippers in the pharmaceutical sector.

A panel offers its perspective on bolstering the temperature monitoring and data sharing process.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Arnon Lopes, head, customer experience, pharma & healthcare, JAS, discusses ways that IoT can support sustainable supply chains at LogiPharma USA in Boston.

A panel offers insight surrounding the industry’s carbon footprint, including ways to begin initiating positive change.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Mark Karhoff, supply chain & DSCSA consultant, National Association of Boards of Pharmacy, discusses the NABP's PULSE program and how it will support supply chains.

With the Nov. 27 deadline fast approaching, is the pharma supply chain ready for full data exchange?

In an interview with Pharma Commerce Editor Nicholas Saraceno, Mark Karhoff, supply chain & DSCSA consultant, National Association of Boards of Pharmacy, discusses insurances to the upcoming DSCSA deadline.

In a final part of his interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, explains the amount of time it takes to see a reduction in annualized drug spend, and offers estimates in terms of percent savings.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, discusses why mitigating the impact of rising costs is imperative, while explaining the benefit of advanced analytics tools.

A study examines if this PCP-large health system dynamic impacts patient outcomes.

The collaboration is centered around meeting track-and-trace requirements.

The manufacturing line producing the company’s branded form of nirsevimab-alip has been approved by the FDA.

A study aims to determine whether there are disparities in burden and treatment across neighborhoods, and if socioeconomic position, race, ethnicity have an impact.